NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences:
Event: 2024 Jefferies Biotech on the Bay Summit
Date: March 12-13, 2024
Location: W Hotel South Beach, Miami, FL.
Event: 13th Annual Napa Valley Biotech Forum
Date: March 26-28, 2024
Presentation: Tuesday, March 26 at 10:30-11:10 A.M. PDT
Location: The J.P. Morgan Office, 560 Mission Street, San Francisco, CA on March 26, and at The Solage Hotel, Calistoga, CA on March 27 - 28.
Event: H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference
Date: March 28, 2024
Fireside Chat: Thursday, March 28, 2024, at 1:00-1:30 P.M. EDT
Location: Virtual
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 (now known as JNJ-2113) as part of Protagonist's Interleukin-23 receptor (IL-23R) collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program. The randomized portion of the Phase 2 REVIVE study was unblinded, showing positive results and is now complete, with an open-label extension underway. The global Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Rusfertide will be co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda entered into in January 2024. The agreement will be effective upon the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 833 500 0061
| Last Trade: | US$38.51 |
| Daily Change: | -0.45 -1.16 |
| Daily Volume: | 280,013 |
| Market Cap: | US$2.300B |
December 09, 2024 November 21, 2024 November 19, 2024 November 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
